An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
An open-label extension study in which patients with multiple sclerosis received GW-1000-02
[named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an
open-label manner.